Which complication can be exacerbated by the use of depolarizing agents in patients with myotonic dystrophy?

The use of depolarizing agents, such as succinylcholine, in patients with myotonic dystrophy can significantly exacerbate hyperthermia. Myotonic dystrophy is characterized by muscle stiffness and myotonia, which can lead to prolonged muscle contractions. When a depolarizing neuromuscular blocker is administered, it can lead to an increase in muscle activity that may trigger a hypermetabolic state, resulting in elevated body temperature and potential hyperthermia.

Additionally, patients with myotonic dystrophy have an abnormal response to muscle relaxants, which could lead to complications such as excessive potassium release during depolarization. However, the primary concern with depolarizing agents in these patients remains the risk of worsening hyperthermia due to increased muscle tone and metabolic activity.

Understanding the risks associated with anesthetic agents in myotonic dystrophy is crucial for safe patient management, especially in surgical settings where neuromuscular blockers are commonly used.